TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04622319
Drug: DS-8201a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
Study: NCT02627846
Drug: Lidocaine with 1:200,000 epinephrine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
Study: NCT02627846
Drug: Lidocaine with 1:200,000 epinephrine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
Study: NCT01101568
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg (single dose) on Days 1 and 10.
Study: NCT01101568
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10mg (single dose) on Days 3 and 12.
Study: NCT01101568
Drug: GSK1292263
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1292263 300mg BID Days 6 to 14.
Study: NCT01207739
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
Study: NCT01207739
Drug: Clarithromycin and hydroxychloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
Study: NCT01207739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
Study: NCT03445013
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Comparator
Study: NCT01356602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
Study: NCT00500149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00058578
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02460588
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2
Study: NCT02460588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
Study: NCT02460588
Drug: Corticosteroid (prednisolone)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive non experimental medication with high dose of corticosteroid.
Study: NCT01614769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
Study: NCT02455518
Drug: Hydrocodone/acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02455518
Drug: Codeine/acetaminophen
Normalized name: PE/codeine/acetaminophen/cpm ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02455518
Drug: Ibuprofen/acetaminophen
Normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00595699
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02560688
Drug: DS-1040b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg single 12-hour intravenous infusion
Study: NCT00426985
Drug: Ketoprofen Topical Patch 20%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02241512
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02241512
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02549690
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
Study: NCT00313859
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02819648
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
Study: NCT00109408
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7.5-20mg po weekly
Study: NCT00456963
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
Study: NCT03196505
Drug: Exparel 266 MG Per 20 ML Injection
Normalized name: Exparel 266 MG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
Study: NCT01450930
Drug: Hydrocortisone intramuscular first
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone intramuscular first
Study: NCT01450930
Drug: Hydrocortisone subcutaneously first
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone subcutaneously first
Study: NCT02936505
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months.
Study: NCT02288156
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: via nasal spray
Study: NCT06522633
Drug: The intervention involves the discontinuation of the opioid.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
Study: NCT02834312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Study: NCT00830037
Drug: IV Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
Study: NCT02552355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of matching placebo during a 12 week exercise training program.
Study: NCT02985125
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
Study: NCT01070784
Drug: Drug: any available COPD treatment; investigator to decide
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
Study: NCT02805218
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03634605
Drug: Tetracycline Topical Ointment
Normalized name: tetracycline Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03634605
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00668343
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/ day
Study: NCT00668343
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg /day
Study: NCT00902174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to imatinib 100 mg film coated tablets
Study: NCT01798706
Drug: Antidiabetic background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
Study: NCT01221675
Drug: Antibody TF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: preciblage with an antibody
Study: NCT02949765
Drug: Iron sulfate 105 mg
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily supplementation with iron sulfate 105 mg 1 pill/day
Study: NCT00471367
Drug: AZD4877
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion administered twice a week for 2 weeks
Study: NCT03273075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
Study: NCT02372903
Drug: Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
Study: NCT02824380
Drug: DA-4001 L
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% minoxidil / low dose of finasteride
Study: NCT01583322
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years.
Study: NCT03107247
Drug: Imaging Time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to be imaged at an additional time point.
Study: NCT00850460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills will consist of lactose and will be given one capsule once daily
Study: NCT03756974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of BX-1, oral solution
Study: NCT01975935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo sham blinded by encapsulation in the same capsules as the study drug arm
Study: NCT00657761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution/12h sc for 7 days
Study: NCT02739594
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
Study: NCT00540449
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet once daily for 96 weeks
Study: NCT03186404
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03782740
Drug: Melatonin 10 mg
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin capsule
Study: NCT03782740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Melatonin capsule
Study: NCT03782740
Drug: Melatonin 20 mg
Normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin capsule
Study: NCT00601523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
Study: NCT00206115
Drug: Seroquel Sustained Release (SR)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00206115
Drug: Seroquel Immediate Release (IR)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00206115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02041546
Drug: Lung lavage with surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02041546
Drug: Bolus surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00968253
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
Study: NCT00968253
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
Study: NCT00968253
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
Study: NCT04072354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet dosed once daily
Study: NCT02090738
Drug: Standard regimen group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02548962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02100748
Drug: TRV130
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 1 - 4 mg will be administered every 4 hours
Study: NCT02100748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered every 4 hours
Study: NCT01871571
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01871571
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00865371
Drug: Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
Study: NCT04246177
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
Study: NCT04246177
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
Study: NCT01525290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lyophilised powder to be reconstituted as solution indistinguishable from the active drug
Study: NCT00343356
Drug: Trement
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01323751
Drug: ACY-1215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
Study: NCT01686230
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Study: NCT01096446
Drug: Intravenous Fat Emulsions
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
Study: NCT02343536
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02193269
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: you will receive 200 mg as a single daily dose for 4 days
Study: NCT03460392
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Study: NCT04785755
Drug: Oral standard diuretics therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
Study: NCT06050343
Drug: Humulin® Regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection at a dose of 0.3 IU / kg
Study: NCT06050343
Drug: Rinsulin® R
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection at a dose of 0.3 IU / kg
Study: NCT00909766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study: NCT01243437
Drug: doxyxcycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer.
Study: NCT00696657
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg, once weekly, s.c. injection
Study: NCT00696657
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg, once weekly, s.c. injection
Study: NCT00696657
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg, once weekly, s.c. injection
Study: NCT00696657
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg with titration, once weekly, s.c. injection
Study: NCT00696657
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg, once weekly, s.c. injection
Study: NCT04473261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty capsule will be given as placebo
Study: NCT04220528
Drug: Capecitabine/Tiggio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2).
Study: NCT00466128
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 50mg PO followed by 25mg PO q6hrs
Study: NCT03312777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline powder overencapsulated
Study: NCT01560546
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/dose/day for 24 weeks
Study: NCT01560546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo on the skin for 24 weeks
Study: NCT04423926
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2 d1
Study: NCT04423926
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 d1
Study: NCT04423926
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60mg/m2 d1-5
Study: NCT01441440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
Study: NCT02929095
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
Study: NCT00159744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 3 weeks
Study: NCT04769583
Drug: placebo based quadriple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient randomized in TT will be treated by double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), clarithromycin (500 mg x 2 per day) and a placebo of metronidazole.
Study: NCT01742624
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral